Abohalaka Reshed, Ercan Selin, Lehtimäki Lauri, Özuygur Ermis Saliha Selin, Lisik Daniil, Bashir Awad Bashir Muwada, Jadhav Radhika, Ekerljung Linda, Wennergren Göran, Lötvall Jan, Pullerits Teet, Backman Helena, Rådinger Madeleine, Nwaru Bright I, Kankaanranta Hannu
Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Allergy Centre, Tampere University Hospital, Tampere, Finland.
J Allergy Clin Immunol Glob. 2025 Mar 8;4(2):100449. doi: 10.1016/j.jacig.2025.100449. eCollection 2025 May.
The use of blood eosinophil count (BEC) as a prognostic biomarker in the management of conditions such as asthma and chronic obstructive pulmonary disease (COPD) may be complicated by factors such as atopy, age, sex, smoking, and comorbidities.
We sought to produce reference values for BEC, considering age, asthma, COPD, and clinical allergy for the general adult population.
The West Sweden Asthma Study constitutes a population-representative clinical epidemiological cohort of randomly selected adults in Western Sweden. From this cohort, 1145 individuals took part in clinical examinations, including skin prick testing, specific IgE, and BEC.
The upper limit (95th percentile) of BEC varied by age. It ranged from 400 to 500 cells/μL in the full sample and from 300 to 400 cells/μL in subjects without asthma, COPD, and clinical allergy (n = 710). Sex, smoking, atopy, clinical allergy, obesity, asthma, COPD, diabetes, and hypertension were statistically significantly associated with higher BEC levels. However, only asthma and clinical allergy in the full sample, and obesity and diabetes in those without asthma, COPD, or clinical allergy, remained statistically significant with higher BEC levels in multivariable regression analyses.
In a population-representative sample, the upper limit of BEC in healthy adults ranged between 300 and 400 cells/μL, varying by age. Age, smoking, obesity, asthma, COPD, and clinical allergy influence BEC levels and should be considered in clinical interpretation.
在哮喘和慢性阻塞性肺疾病（COPD）等疾病的管理中，将血液嗜酸性粒细胞计数（BEC）用作预后生物标志物可能会因特应性、年龄、性别、吸烟和合并症等因素而变得复杂。
我们试图针对一般成年人群，考虑年龄、哮喘、COPD和临床过敏情况，得出BEC的参考值。
瑞典西部哮喘研究是瑞典西部随机选取的成年人的具有人群代表性的临床流行病学队列。从该队列中，1145人参加了临床检查，包括皮肤点刺试验、特异性IgE和BEC检测。
BEC的上限（第95百分位数）随年龄而异。在整个样本中，其范围为400至500个细胞/μL，在无哮喘、COPD和临床过敏的受试者中（n = 710）为300至400个细胞/μL。性别、吸烟、特应性、临床过敏、肥胖、哮喘、COPD、糖尿病和高血压与较高的BEC水平在统计学上显著相关。然而，在多变量回归分析中，仅整个样本中的哮喘和临床过敏，以及无哮喘、COPD或临床过敏者中的肥胖和糖尿病，与较高的BEC水平仍具有统计学显著性。
在具有人群代表性的样本中，健康成年人的BEC上限在300至400个细胞/μL之间，随年龄而异。年龄、吸烟、肥胖、哮喘、COPD和临床过敏会影响BEC水平，在临床解读中应予以考虑。
